Special Topics in Toxicology

  • You must log in to register
    • Nonmember - $350
    • Full Member - $225
    • Associate Member - $225
    • Emeritus Member - $225
    • Government Associate Member - $225
    • Government Full Member - $225
    • Postdoctoral Researcher/Transitional Member - $125
    • Student Member - $125

To further its mission to educate, lead, and serve, the American College of Toxicology offers an eLearning Seminar focused on Special Topics in Toxicology. This eLearning Seminar of six modules provides continuing education opportunities to practicing toxicology professionals. The modules feature recognized experts in the fields of inhalation toxicology, dermal toxicology, neurotoxicology, juvenile animal studies, in silico/computational toxicology, and threshold/benchmark dose setting. Modules are available for purchase individually or as a discounted set of six modules. Registrants have on-demand access to the modules for 30 days from the time each archive is first accessed. Each module is 90 minutes or less in duration.

Disclaimer:

This seminar reflects the views of the speaker and should not be construed to represent the views or policies of the American College of Toxicology. Examples presented in this seminar may have required unique strategies that do not necessarily apply to other modalities or situations. Regulatory guidelines and best practices are constantly evolving, and the viewer is encouraged to independently confirm their understanding with what was presented in this seminar.  

  • Contains 3 Component(s) Recorded On: 09/29/2022

    Special Topics Series

    image
    image


    This eLearning module will focus on the principles of juvenile toxicology. The lecture will be offered with two main themes: the first will address whether a juvenile animal study should be conducted, followed by a focus on how it could be conducted. The first section will provide an overview of juvenile toxicology from a regulatory perspective. This will include the ICH S11 guidance for nonclinical juvenile animal testing to support pediatric medicine development (released in 2020), which proposes a weight-of-evidence approach to decide whether a juvenile animal study is warranted. If a study is warranted, this exercise informs the main objectives of the juvenile animal study, including any customized additional endpoints to the ‘core’ endpoints provided in ICH S11. The second part of the session will focus on study design and delivery approaches to juvenile animal testing for pharmaceutical and nonpharmaceutical industries. Topics addressed will include selection of juvenile toxicology species, age of the animals during treatment, both with strong consideration of comparative organ development. As ADME systems are often immature in juvenile animals, dose range-finding approaches will be discussed in detail.  Since rodent juvenile animal studies are the most common, study design considerations for treatment of preweaning animals within a litter will be reviewed. Lastly, interpretation considerations unique to juvenile animal studies and application of results to human risk assessment will be discussed with a focus on pharmaceuticals. 

    Susan Laffan, PhD

    Susan Laffan, PhD

    Head of the Nonclinical Global Investigative Safety

    GlaxoSmithKline

    Susan Laffan is currently a Head of the Nonclinical Global Investigative Safety group at GlaxoSmithKline, she is a toxicologist with over 18 years of pharmaceutical industry experience. Susan is the nonclinical chair of the GSK’s pediatric advisory network providing advice to drug development teams on their pediatric development plans. Dr. Laffan represented PhRMA on the ICH S11 Working Group. She is an expert in reproductive and developmental toxicology and has been directly involved in the drug development teams supporting the safety assessment of compounds from discovery through post-marketing. Susan earned a PhD in toxicology from the University of North Carolina at Chapel Hill, conducting her dissertation at the USEPA, Research Triangle Park, NC. In addition, she is on the ILSI/HESI DART Technical Committee.

  • Contains 4 Component(s) Recorded On: 12/23/2025

    Special Topics Series

    image
    image


    (Quantitative) structure-activity relationship [(Q)SAR] modeling has a long history of use in drug development. However, the International Council for Harmonization (ICH) M7 guideline for assessing the mutagenic potential of drug impurities stands as a milestone in the regulatory acceptance of (Q)SAR. The guideline describes how complementary modeling methodologies can be used in combination with expert knowledge to support classifying an impurity as mutagenic or non-mutagenic, which in turn determines acceptable levels of the impurity during synthesis and degradation. The selection of appropriate (Q)SAR models for ICH M7 impurity qualification requires knowledge of how models are constructed and how predictions are generated. Technical considerations such as the molecular descriptors used to interpret chemical structure, the type of algorithm used to extract structure-activity relationships, or the way the model confirms it can make a reliable prediction are critical for the user to understand so that the model output is interpreted correctly. 

    Part One of this seminar will provide an introduction to the basic concepts and technical considerations of (Q)SAR modeling. Key concepts, such as reconciling conflicting predictions or applying the OECD Validation Principles to assess model suitability will be covered, as well as the limitations of the methodology. An introduction to expert knowledge and strategies for structural analog searching will be provided along with best practices for the comprehensive reporting of results in regulatory submissions. In addition, this session will provide a pharmaceutical industry perspective on the regulatory use of (Q)SAR, including a general process for evaluating mutagenic potential with an emphasis on impurities, generation of predictions, application of expert knowledge, and final classification. The utility of read-across and case studies will be used to emphasize key concepts and demonstrate best practices. 

    Part Two—Supplemental Session will provide an update on the changes to the most recent ICH M7 guidance as well as a review of the main principles of the M7 guidance, including impurity evaluation, hazard assessment and classification, as well as risk characterization and control. During the progression through development, there are occasions where novel impurities may arise due to changed manufacturing processes, or impurities that are discovered after safety studies have been concluded. The EMA has published a reflection paper that covers qualification of non-mutagenic impurities (NMI) using new approach methodologies and methods to set acceptable levels of NMIs. The seminar will also cover a review of the salient points of the EMA paper. 

    Lisa D. Beilke, MSPH, PhD, DABT, ATS

    Lisa D. Beilke, MSPH, PhD, DABT, ATS

    Consultant

    Toxicology Solutions, Inc.

    Dr. Lisa Beilke has over 25 years of experience working in various fields of toxicology in support of novel therapeutics. She has worked for small contract laboratories, start-up biotechs, as well as large pharma (Pfizer, Gilead). She earned her PhD in Pharmacology & Toxicology from the University of Arizona, as well as her BS and MS (Public Health/Toxicology) degrees from San Diego State University. Dr. Beilke has been an independent consultant with Toxicology Solutions, Inc. for the last 13 years and has focused on providing toxicology services to the pharmaceutical industry, with a specialty in in silico toxicity predictions for potential genotoxic impurities and risk assessment. Dr. Beilke has worked closely with colleagues in the computational toxicology field over the years and has several publications in this field, including collaborations with Leadscope on in silico protocols. As a consultant, Dr. Beilke has worked with clients on various therapeutic areas (dermatology, oncology, metabolic diseases, cardiovascular, etc.) and compound types (e.g., peptides, polymers, antibodies, dye conjugates, etc.).

    Dr. Beilke has a long history of involvement with various toxicology organizations. As a diplomat of ABT, she was part of the group that worked on the standardization of the certification examination. She has been a member of the ACT since 1999 and has served on the Education (2009–2011) and Finance Committees (2011–2014), as a Councilor (2016–2018), and was presented with the Young Investigator Award in 2013. She is also on the Editorial Board of the International Journal of Toxicology (2013–present). She is a full member of the SOT, where she is Past President of the Computational Toxicology Specialty Section (CTSS), which she co-developed as a new Specialty Section.

    Naomi Kruhlak, PhD

    Naomi Kruhlak, PhD

    Computational Toxicologist

    US FDA

    Dr. Naomi Kruhlak has worked for the US FDA’s Center for Drug Evaluation and Research (CDER) as a computational toxicologist for 18 years, developing and applying (quantitative) structure-activity relationship ((Q)SAR) models to support the regulatory review of pharmaceuticals. She is the Scientific Lead for CDER’s Computational Toxicology Consultation Service and is the Principal Investigator on three FDA/CDER Research Collaboration Agreements with commercial (Q)SAR software vendors, as well as an Inter-Agency Agreement with NIH generating in silico-based drug safety predictions. Dr. Kruhlak has published 42 peer-reviewed articles describing data standardization, transformation, and classification for modeling purposes, and the creation and application of (Q)SAR models with chemical interpretability. Dr. Kruhlak holds BSc and PhD degrees in chemistry from the University of Salford, England, and the University of Calgary, Canada, respectively.

    Mark Powley, PhD

    Mark Powley, PhD

    Distinguished Research Scientist

    Merck & Co., Inc.

    Mark W. Powley received a PhD in toxicology from Purdue University and completed postdoctoral training at the University of North Carolina – Chapel Hill. From 2004 to 2009, he worked in the general toxicology, biochemical toxicology, and genetic toxicology groups at Merck Research Laboratories. In 2009, Mark moved to the US FDA Center for Drug Evaluation and Research (CDER), Office of New Drugs. In addition to reviewing nonclinical data, Mark co-chaired several CDER pharmacology/toxicology subcommittees, including those focused on genetic toxicology and computational toxicology. Mark rejoined Merck Research Laboratories in 2017 and currently works in the genetic toxicology group. His primary role involves supporting both mutagenic and non-mutagenic impurity safety assessment.

  • Contains 3 Component(s) Recorded On: 12/23/2025

    Special Topics Series

    image
    image


    This introductory lecture will cover the topics of neurotoxicology and neurodevelopment. After a brief discussion of the regulatory guidelines and guidance documents that govern neurotoxicology studies, the focus of the lecture will be on describing functional and structural assessments used to characterize alterations in nervous system structure and function. Several types of functional tests will be discussed in the context of neurobiology, regulatory requirements, the advantages and disadvantages of each test, and the species that can be tested in each assessment, using positive control data for illustration, where available. This section of the lecture will end with a discussion of generic factors that can influence neurobehavior data. The second half of the lecture will focus on structural assessments of the brain, and the central and peripheral nervous systems. Options available for neurohistopathology, immunohistochemistry, and brain morphometry will be discussed. The discussion will again focus on the advantages and disadvantages of each stain, with illustrative micrographs. At the end, general concepts of adult versus developmental (juvenile) neurotoxicity will be introduced, followed by the final few slides focused on data interpretation, the relationship between functional and structural deficits, and the importance of using the weight-of-the-evidence approach to draw conclusions regarding treatment-relatedness and adversity. 

    Pragati Coder, PhD, DABT

    Pragati Coder, PhD, DABT

    Global Scientific Lead for Developmental and Reproductive Toxicology

    Charles River Laboratories

    Dr. Pragati Coder is a Global Scientific Lead for Developmental and Reproductive Toxicology (DART; C&C) at Charles River Laboratories. She also serves as the Senior Director and Scientific Lead for DART, Juvenile and Neurotoxicology for Charles River’s site in Ashland, Ohio. She received her doctorate in molecular biology from the Indian Institute of Technology-Bombay, India, and was a postdoctoral fellow in reproductive toxicology at the College of Pharmacy, The University of Texas at Austin. Dr. Coder is board-certified as a Diplomate of the American Board of Toxicology and serves as a subject matter expert for developmental, reproductive, endocrine, neurotoxicity, and juvenile toxicity studies that support product development programs for pharmaceutical, (agro) chemical, and veterinary medical products.

    She is an active member of the international DART scientific community and several professional organizations, including the Society of Toxicology, Society for Birth Defects Research and Prevention, Health and Environmental Science Institute (HESI-DART), European Teratology Society, and the Middle Atlantic Reproduction and Teratology Association (MARTA) where she has served in various official capacities. She is currently the President of the Society for Birth Defects Research and Prevention.

  • Contains 3 Component(s) Recorded On: 01/20/2020

    Special Topics Series

    image
    image


    This presentation will begin with an overview of the anatomy, physiology, and function of the respiratory tract, including key species differences that should be considered when interpreting the results of animal inhalation toxicology studies for human risk assessment. Inhalation toxicology studies are technically very challenging; unlike other routes of exposure where the exact dose administered is known, for inhaled studies the given dose needs to be calculated based on a series of measurements, calculations, and assumptions. The design and conduct of these studies will be described, including inhalation exposure systems for different species, inhalation devices and methods of aerosol generation for different physical forms of test substance (nebulizers, metered-dose inhalers and other dry powder generators), understanding and measuring inhaled dose, and common toxicity findings (including irritation, inflammation and hyper/metaplasia). Finally, the use of inhaled toxicity study data for risk assessment will be discussed.  

    Joanne Kilgour, MSc, PhD, ERT

    Joanne Kilgour, MSc, PhD, ERT

    Consultant Toxicologist

    Regulatory Science Associates

    Dr. Kilgour is a Consultant Toxicologist at Regulatory Science Associates. She has been an Independent Consultant since 2016, focusing on inhaled and oncology projects. She provides strategic nonclinical toxicology advice to small, medium, and large Pharma on product development from Phase 1 through to marketing authorization. Dr. Kilgour also supports development via program design and management, regulatory document preparation, and representation at regulatory meetings. She has 28 years of product development experience in both Pharma and Agrochemicals (including 10 years at both Syngenta Central Toxicology Laboratory and AstraZeneca). Dr. Kilgour is the Chair of the Association of inhalation toxicologists (AIT) and previous Scientific Meetings and the Secretary and Chair of the Education Subcommittee of the British Toxicology Society. She was previously involved in a cross-industry Working Group on challenges of Alveolar Macrophage findings in Inhaled Drug Development (Forbes, et al, 2014) and is currently leading a Pharma-wide Working Group on Inhaled Biologics, aiming to publish two papers in Toxicologic Pathology in 2020. She is an invited speaker on Inhalation Toxicology at the Birmingham MSc Toxicology Course, ACT Course, Educational Workshop for Regulators at FDA in 2013, and European Chemicals Agency (ECHA) in 2017.

  • Contains 3 Component(s) Recorded On: 01/20/2020

    Special Topics Series

    image
    image


    The skin is the largest organ in the body by area, if not by weight, and is of great interest to toxicologists. In this presentation, we will consider the anatomy of the skin and topics such as metabolism, penetration of drugs, and toxicology and pharmacology, including the relationship between dermal drug application and systemic toxicity. The presentation will have a particular focus on drug delivery and aspects of purpose (not all dermally applied drugs are intended to have an effect in the skin), formulation/dosage forms, penetration, and kinetics. From a toxicological testing viewpoint, we will consider species selection (including selection of both non-rodent and rodent species in programme design strategies), and relevance to humans; study design and study performance will be discussed.   

    Andrew Makin, MSc

    Andrew Makin, MSc

    Consultant

    Andrew Makin Preclinical Consulting ApS

    Andrew Makin has almost 40 years of practical, hands-on experience in design, management, conduct and overview of preclinical programmes and individual studies. He has a first degree in biology and psychology from the University of Keele in England and an MSc in applied zoology from the University of Wales. He is a Member of the Royal Society of Biology and is a Registered Toxicologist. Dr. Makin’s experience in toxicology is in the areas of preclinical pharmaceutical development, and related subjects. He has a significant understanding of the scientific and regulatory requirements in these fields. Working in Contract Research, first in the UK with HLS from 1980 to 2001, and subsequently in Denmark from 2002 until 2019 with Scantox, LAB Research and Citoxlab, he has gained a very broad understanding of the needs of customers from a wide variety of different companies and approaches, from small (virtual) companies all the way up to Big Pharma. Dr. Makin’s work has involved all aspects of the process from identifying the needs of the customer through to execution of projects and interpretation of study results. During this time, he worked with most animal species and with most study types, and naturally, during his time at Scantox, this included a significant focus on the Göttingen minipig and projects involving the development of dermal and topical drugs and devices. Having worked with projects in all the major regions of the world, he has a fundamental understanding of the needs of drug development companies globally. Since 2019 he has taken this experience into the world of consulting, establishing his own company.

  • Contains 3 Component(s) Recorded On: 01/20/2020

    Special Topics Series

    image
    image


    Characterizing and interpreting the dose-response relationship is perhaps the most challenging task in health risk assessment. Toxicologists understand that “the dose makes the poison”, but the types of effects under consideration and the magnitude of their deviation from the “normal” range pose separate and appreciable challenges. In the context of EPA’s Reference Dose paradigm, some effects may not represent adverse changes; for other effects, some deviations, even if statistically significant, have been interpreted to not represent biologically meaningful changes. Application of benchmark dose modeling allows risk assessors to estimate doses associated with predetermined levels of response, often 10% for non-cancer effects, 5% for developmentally toxic effects, and 1% for cancer. These values and traditional NOAEL or LOAEL values may be used as point of departure (POD) values for determining risk. Whether defined in animals or humans in vivo, the POD is the “jumping off point” from which we depart from the realm of empirical dose-response data and begin to extrapolate the identified “point” to human exposure conditions that may differ relative to species, human population subgroup, exposure duration, and/or magnitude of effect. While the POD identified in vivo may (might, can) represent a threshold, the further that POD is extrapolated from the conditions under which it is identified, the less certain it becomes as a threshold (in fact, its name changes and its definition often acknowledges a potential range of uncertainty). The decisions surrounding what effect is selected as the critical effect, the acceptability of the study design employed to develop dose-response data, the selection of the point of departure, and the methods used to extrapolate the POD to the risk value each embody multiple considerations and decisions, carrying with them different levels of bias toward health conservatism – a condition which may not be fully acknowledged or appreciated. This presentation will explore aspects of risk value development focused on identifying and extrapolating the biological threshold for adversity.

    John Lipscomb, PhD, DABT, ATS

    John Lipscomb, PhD, DABT, ATS

    Adjunct Professor

    University of Louisville

    Dr. Lipscomb began his career as a biologist at the National Center for Toxicological Research in Jefferson, Arkansas. He later served as a Captain (research toxicologist) in the US Air Force, where he earned the Air Force Achievement Medal for his pioneering work on the military’s first large-scale investigation of human metabolic variability. He completed his federal career as a toxicologist and risk assessor in EPA’s National Center for Environmental Assessment and National Homeland Security Research Center in Ohio, where he was a chemical manager for three different risk assessment programs and led the development of EPA guidance for quantitative risk assessment and emergency exposure guidance values. Dr. Lipscomb has over 100 peer-reviewed publications, book chapters, and government technical reports. His interests include quantitative risk assessments of single chemicals and chemical mixtures, in vitro to in vivo extrapolation, toxicokinetics, and non-default extrapolations of dosimetry among and between species. Dr. Lipscomb is a Diplomate of the American Board of Toxicology and a Fellow of the Academy of Toxicological Sciences. He serves on the Health Advisory Board for NSF International and the American Industrial Hygiene Association’s Emergency Response Planning Committee. He is a past president of the Society for Risk Analysis’s Ohio chapter, the Society of Toxicology’s Risk Assessment Specialty Section and Ohio Valley regional chapter, as well as the American Board of Toxicology. He serves on the Editorial Board for Toxicological Sciences and is an Associate Editor for Toxicology Mechanisms and Methods, and Toxicology Reports. Dr. Lipscomb holds bachelor’s and master’s degrees in biology from the University of Central Arkansas and a PhD in interdisciplinary toxicology from the University of Arkansas for Medical Sciences, and is an adjunct professor of Toxicology and course director for Human Health Risk Assessment in the Department of Pharmacology and Toxicology at the University of Louisville.

Registration Fees:

Seminar registration is restricted to single person use only. Please note that all eLearning sales are final. No cancellations or refunds will be allotted after payment is processed.

Registration Type Set/Module 1–6
ACT Member $225
ACT Student/Transitional/Postdoctoral Researcher Member $125
Nonmember $350

*Fees are assessed according to membership status at the time of purchase. There are no exceptions and no refunds after payment has been processed.

The Special Topics in Toxicology eLearning Seminar content will only be available until December 31, 2027.